{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:23:25Z","timestamp":1790519005746,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Visceral leishmaniasis (VL) is severe and potentially fatal. Brazil is one of the countries with the greatest endemicity for the disease in the world. The reduction of CD4\n                      <jats:sup>+<\/jats:sup>\n                      T lymphocytes, B cells activation and high levels of inflammatory cytokines (IL-6\/IL-8\/TNF\/IL-1\u03b2), plasma LPS, soluble CD14, anti-\n                      <jats:italic>Leishmania<\/jats:italic>\n                      IgG3 and low leptin levels are involved in the immunopathogenesis of VL, most associated with severe VL. Despite relapses occurring in about 4\u20135% of patients with VL not associated with HIV infection, the factors underlying relapses are little known. Our aim was to identify clinical, laboratory and immunological parameters that may be associated with recurrences in VL.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Fifteen VL patients recruited from Hospital Eduardo de Menezes (BH-MG) were grouped into relapsing (R-VL,\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u20095) and non-relapsing (NR-VL,\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u200910) and evaluated during active disease, immediately after treatment (post-treatment) and 6 months post-treatment (6mpt). Clinical and laboratory data obtained from medical records were correlated with CD4\n                      <jats:sup>+<\/jats:sup>\n                      and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell counts and anti-\n                      <jats:italic>Leishmania<\/jats:italic>\n                      Igs and IL-6 plasma levels and compared to those parameters of ten healthy controls.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      During the active phase of VL, despite similarity in the clinical symptoms, the rates of thrombocytopenia, elevated transaminases (AST and ALT) and hyperbilirubinemia were higher in the NR-VL group compared to R-VL (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u20090.05), a profile reversed during the post-treatment phase. All patients had low CD4\n                      <jats:sup>+<\/jats:sup>\n                      T counts in active phase, however, NR-VL patients had a higher gain of this cell type than R-VL in the post-treatment (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u20090.05). There was a significant reduction in IgG3 levels during the follow-up in the NR-VL group compared to the R-VL, especially at 6mpt (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u20090.05). In addition, IgG3 levels were negatively correlated with CD4\n                      <jats:sup>+<\/jats:sup>\n                      T counts in the R-VL group (\n                      <jats:italic>r<\/jats:italic>\n                      \u00a0=\u2009\u2212\u20090.52). Elevated levels of IL-6 were observed in active VL and correlated with clinical markers of severity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>During active phase of VL, the NR-VL patients presented more severe laboratorial abnormalities compared to R-VL, probably because the latter had already received previous treatment. On the other hand, R-VL exhibited greater impairment of immune reconstitution and a high degree of B lymphocyte activation, which must be a factor that favored relapses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-021-06051-5","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T22:18:50Z","timestamp":1618870730000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["High levels of anti-Leishmania IgG3 and low CD4+ T cells count were associated with relapses in visceral leishmaniasis"],"prefix":"10.1186","volume":"21","author":[{"given":"Renata Caetano","family":"Kuschnir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo Soares","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rita Teixeira","family":"Dutra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludmila","family":"de Paula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luciana","family":"Silva-Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Corr\u00eaa-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"da Costa Cruz Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glaucia","family":"Cota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna Reis","family":"Santos-Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alda Maria","family":"Da-Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,20]]},"reference":[{"key":"6051_CR1","unstructured":"Minist\u00e9rio da Sa\u00fade (BR), Secretaria de Vigil\u00e2ncia em Sa\u00fade. Guia de vigil\u00e2ncia em sa\u00fade. 2nd. Brasil: Minist\u00e9rio da Saude; 2017. Available at: https:\/\/portalarquivos2.saude.gov.br\/images\/PDF\/2017\/outubro\/16\/Volume-Unico-2017.pdf. Accessed Dec 2019."},{"key":"6051_CR2","unstructured":"World Health Organization. Leishmaniasis. 2018. Available at: https:\/\/www.who.int\/leishmaniasis. Accessed Dec 2019."},{"key":"6051_CR3","unstructured":"Pan American Health Organization, World Health Organization. Leishmaniasis. Epidemiological report of the Americas: 2019. Available at: www.paho.org\/leishmaniasis. Accessed Dec 2019."},{"key":"6051_CR4","unstructured":"Brasil, Minist\u00e9rio da Sa\u00fade. Sistema de Informa\u00e7\u00e3o de Agravos de Notifica\u00e7\u00e3o - Banco de dados do Sistema \u00danico de Sa\u00fade - DATASUS. Available at: http:\/\/tabnet.datasus.gov.br\/cgi\/deftohtm.exe?sinannet\/cnv\/leishvmg.def. Accessed Sept 2020."},{"issue":"8","key":"6051_CR5","doi-asserted-by":"publisher","first-page":"e572","DOI":"10.1016\/j.ijid.2012.12.024","volume":"17","author":"L Saporito","year":"2013","unstructured":"Saporito L, Giammanco GM, De Grazia S, Colomba C. Visceral leishmaniasis: host\u2013parasite interactions and clinical presentation in the immunocompetent and in the immunocompromised host. Int J Infect Dis. 2013;17(8):e572\u20136. https:\/\/doi.org\/10.1016\/j.ijid.2012.12.024.","journal-title":"Int J Infect Dis"},{"key":"6051_CR6","volume-title":"Leishmaniose visceral (calazar)","author":"J Rodrigues da Silva","year":"1957","unstructured":"Rodrigues da Silva J. Leishmaniose visceral (calazar). Rio de Janeiro: Tese [Concurso para provimento efetivo do cargo de professor catedr\u00e1tico da cadeira de Clinica das Doen\u00e7as Tropicais e Infectuosas da Faculdade Nacional de Medicina da Universidade do Brasil]. Sociedade Editora e Gr\u00e1fica Ltda; 1957."},{"key":"6051_CR7","doi-asserted-by":"publisher","unstructured":"Rossi M, Fasel N. How to master the host immune system? Leishmania parasites have the solutions! Int Immunol. 2017. https:\/\/doi.org\/10.1093\/intimm\/dxx075.","DOI":"10.1093\/intimm\/dxx075"},{"issue":"11","key":"6051_CR8","doi-asserted-by":"publisher","first-page":"e877","DOI":"10.1371\/journal.pntd.0000877","volume":"4","author":"MJAQ Sampaio","year":"2010","unstructured":"Sampaio MJAQ, Cavalcanti NV, Alves JGB, Fernandes Filho MJC, Correia JB. Risk factors for death in children with visceral Leishmaniasis. PLoS Negl Trop Dis. 2010;4(11):e877. https:\/\/doi.org\/10.1371\/journal.pntd.0000877.","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"6051_CR9","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1590\/0037-8682-0258-2016","volume":"49","author":"DL Costa","year":"2016","unstructured":"Costa DL, Rocha RL, Chaves EBF, Batista VGV, Costa HL, Costa CHN. Predicting death from kala-azar: construction, development, and validation of a score set and accompanying software. Rev Soc Bras Med Trop. 2016;49(6):728\u201340. https:\/\/doi.org\/10.1590\/0037-8682-0258-2016.","journal-title":"Rev Soc Bras Med Trop"},{"issue":"4","key":"6051_CR10","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1093\/infdis\/163.4.853","volume":"163","author":"M Barral-Netto","year":"1991","unstructured":"Barral-Netto M, Badar\u00f3 R, Barral A, Almeida RP, Santos SB, Badar\u00f3 F, et al. Tumor necrosis factor (Cachectin) in human visceral leishmaniasis. J Infect Dis. 1991;163(4):853\u20137. https:\/\/doi.org\/10.1093\/infdis\/163.4.853.","journal-title":"J Infect Dis"},{"issue":"7","key":"6051_CR11","doi-asserted-by":"publisher","first-page":"e1198","DOI":"10.1371\/journal.pntd.0001198","volume":"5","author":"JR Santos-Oliveira","year":"2011","unstructured":"Santos-Oliveira JR, Regis EG, Leal CRB, Cunha RV, Bozza PT, Da-Cruz AM. Evidence that lipopolysaccharide may contribute to the cytokine storm and cellular activation in patients with visceral leishmaniasis. PLoS Negl Trop Dis. 2011;5(7):e1198. https:\/\/doi.org\/10.1371\/journal.pntd.0001198.","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"6051_CR12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1179\/2047773213Y.0000000078","volume":"107","author":"DL Costa","year":"2013","unstructured":"Costa DL, Rocha RL, Carvalho RMA, Lima-Neto AS, Harhay MO, Costa CHN, et al. Serum cytokines associated with severity and complications of kala-azar. Pathog Glob Health. 2013;107(2):78\u201387. https:\/\/doi.org\/10.1179\/2047773213Y.0000000078.","journal-title":"Pathog Glob Health"},{"issue":"1","key":"6051_CR13","doi-asserted-by":"publisher","first-page":"e0004375","DOI":"10.1371\/journal.pntd.0004375","volume":"10","author":"PL Santos","year":"2016","unstructured":"Santos PL, de Oliveira FA, Santos MLB, Cunha LCS, Lino MTB, de Oliveira MFS, et al. The Severity of Visceral Leishmaniasis Correlates with Elevated Levels of Serum IL-6, IL-27 and sCD14. PLoS Negl Trop Dis. 2016;10(1):e0004375. https:\/\/doi.org\/10.1371\/journal.pntd.0004375.","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"6051_CR14","doi-asserted-by":"publisher","first-page":"e0005486","DOI":"10.1371\/journal.pntd.0005486","volume":"11","author":"RLL Silva","year":"2017","unstructured":"Silva RLL, Santos MB, Almeida PLS, Barros TS, Magalh\u00e3es L, Cazzaniga RA, et al. sCD163 levels as a biomarker of disease severity in leprosy and visceral leishmaniasis. PLoS Negl Trop Dis. 2017;11(3):e0005486. https:\/\/doi.org\/10.1371\/journal.pntd.0005486.","journal-title":"PLoS Negl Trop Dis"},{"issue":"8","key":"6051_CR15","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1365-3024.2008.01036.x","volume":"30","author":"NA Ansari","year":"2008","unstructured":"Ansari NA, Kumar R, Raj A, Salotra P. Elevated levels of IgG3 and IgG4 subclass in paediatric cases of kala azar. Parasite Immunol. 2008;30(8):403\u20139. https:\/\/doi.org\/10.1111\/j.1365-3024.2008.01036.x.","journal-title":"Parasite Immunol"},{"issue":"11","key":"6051_CR16","doi-asserted-by":"publisher","first-page":"e12669","DOI":"10.1111\/pim.12669","volume":"41","author":"B Singh","year":"2019","unstructured":"Singh B, Bhushan Chauhan S, Kumar R, Singh SS, Ng S, Amante F, et al. A molecular signature for CD8+ T cells from visceral leishmaniasis patients. Parasite Immunol. 2019;41(11):e12669. https:\/\/doi.org\/10.1111\/pim.12669.","journal-title":"Parasite Immunol"},{"issue":"3","key":"6051_CR17","doi-asserted-by":"publisher","first-page":"e0214413","DOI":"10.1371\/journal.pone.0214413","volume":"14","author":"Fievez AMdC, Silva-Freitas ML, Sous","year":"2019","unstructured":"Fievez AMdC, Silva-Freitas ML, Sousa AdQ, Santos-Oliveira JR, Da-Cruz AM. Lower levels of leptin are associated with severity parameters in visceral leishmaniasis patients. PLoS One. 2019;14(3):e0214413. https:\/\/doi.org\/10.1371\/journal.pone.0214413.","journal-title":"PLoS One"},{"issue":"1","key":"6051_CR18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1471-2334-8-86","volume":"8","author":"FA Bozza","year":"2008","unstructured":"Bozza FA, Cruz OG, Zagne SMO, Azeredo EL, Nogueira RMR, Assis EF, et al. Multiplex cytokine profile from dengue patients: MIP-1beta and IFN-gamma as predictive factors for severity. BMC Infect Dis. 2008;8(1):86. https:\/\/doi.org\/10.1186\/1471-2334-8-86.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"6051_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1475-2875-9-13","volume":"9","author":"BB Andrade","year":"2010","unstructured":"Andrade BB, Reis-Filho A, Souza-Neto SM, Clar\u00eancio J, Camargo LMA, Barral A, et al. Severe Plasmodium vivax malaria exhibits marked inflammatory imbalance. Malar J. 2010;9(1):13. https:\/\/doi.org\/10.1186\/1475-2875-9-13.","journal-title":"Malar J"},{"issue":"4","key":"6051_CR20","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1590\/s0037-86822010000400010","volume":"43","author":"CHN Costa","year":"2010","unstructured":"Costa CHN, Werneck GL, Costa DL, Holanda TA, Aguiar GB, Carvalho AS, et al. Is severe visceral leishmaniasis a systemic inflammatory response syndrome? A case control study. Rev Soc Bras Med Trop. 2010;43(4):386\u201392. https:\/\/doi.org\/10.1590\/s0037-86822010000400010.","journal-title":"Rev Soc Bras Med Trop"},{"key":"6051_CR21","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.actatropica.2017.05.011","volume":"172","author":"GF Cota","year":"2017","unstructured":"Cota GF, Sousa MR, Assis TSM, Pinto BF, Rabello A. Exploring prognosis in chronic relapsing visceral leishmaniasis among HIV infected patients: circulating Leishmania DNA. Acta Trop. 2017;172:186\u201391. https:\/\/doi.org\/10.1016\/j.actatropica.2017.05.011.","journal-title":"Acta Trop"},{"issue":"4","key":"6051_CR22","doi-asserted-by":"publisher","first-page":"e2816","DOI":"10.1371\/journal.pntd.0002816","volume":"8","author":"GF Cota","year":"2014","unstructured":"Cota GF, Sousa MR, Mendon\u00e7a ALP, Patrocinio A, Assuncao LS, de Faria SR, et al. Leishmania-HIV co-infection: clinical presentation and outcomes in an urban area in Brazil. PLoS Negl Trop Dis. 2014;8(4):e2816. https:\/\/doi.org\/10.1371\/journal.pntd.0002816.","journal-title":"PLoS Negl Trop Dis"},{"issue":"12","key":"6051_CR23","doi-asserted-by":"publisher","first-page":"e0167512","DOI":"10.1371\/journal.pone.0167512","volume":"11","author":"ML Silva-Freitas","year":"2016","unstructured":"Silva-Freitas ML, Cota GF, Machado-de-Assis TS, Giacoia-Gripp C, Rabello A, Da-Cruz AM, et al. Immune activation and bacterial translocation: a link between impaired immune recovery and frequent visceral Leishmaniasis relapses in HIV-infected patients. PLoS One. 2016;11(12):e0167512. https:\/\/doi.org\/10.1371\/journal.pone.0167512.","journal-title":"PLoS One"},{"key":"6051_CR24","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3389\/fimmu.2020.00953","volume":"11","author":"ML Silva-Freitas","year":"2020","unstructured":"Silva-Freitas ML, Corr\u00eaa-Castro G, Cota GF, Giacoia-Gripp C, Rabello A, Dutra JT, et al. Impaired Thymic output can be related to the low immune reconstitution and T cell repertoire disturbances in relapsing visceral Leishmaniasis associated HIV\/AIDS patients. Front Immunol. 2020;11:953. https:\/\/doi.org\/10.3389\/fimmu.2020.00953.","journal-title":"Front Immunol"},{"key":"6051_CR25","unstructured":"Brasil, Minist\u00e9rio da Sa\u00fade. Sistema de Informa\u00e7\u00e3o de Agravos de Notifica\u00e7\u00e3o. Available at: http:\/\/portalsinan.saude.gov.br\/images\/documentos\/Agravos\/Leishmaniose%20Visceral\/LV_v5.pdf. Accessed Sept 2019."},{"issue":"1","key":"6051_CR26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s40249-018-0491-7","volume":"7","author":"EA Gebreyohannes","year":"2018","unstructured":"Gebreyohannes EA, Bhagvathula AS, Abegaz TM, Seid MA. Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis. Infect Dis Poverty. 2018;7(1):108. https:\/\/doi.org\/10.1186\/s40249-018-0491-7.","journal-title":"Infect Dis Poverty"},{"issue":"1","key":"6051_CR27","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1186\/s13071-019-3628-z","volume":"12","author":"L Horrillo","year":"2019","unstructured":"Horrillo L, Castro A, Mat\u00eda B, Molina L, Garc\u00eda-Mart\u00ednez J, Jaqueti J, et al. Clinical aspects of visceral leishmaniasis caused by L. infantum in adults. Ten years of experience of the largest outbreak in Europe: what have we learned? Parasit Vectors. 2019;12(1):359. https:\/\/doi.org\/10.1186\/s13071-019-3628-z.","journal-title":"Parasit Vectors"},{"key":"6051_CR28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ijid.2020.02.028","volume":"95","author":"JC Sim\u00e3o","year":"2020","unstructured":"Sim\u00e3o JC, Vict\u00f3ria C, Fortaleza CMCB. Predictors of relapse of visceral leishmaniasis in inner S\u00e3o Paulo state, Brazil. Int J Infect Dis. 2020;95:44\u20139. https:\/\/doi.org\/10.1016\/j.ijid.2020.02.028.","journal-title":"Int J Infect Dis"},{"key":"6051_CR29","volume-title":"Coinfec\u00e7\u00e3o leishmaniose visceral e Aids no Brasil, 2001 a 2010","author":"MLS Gomes","year":"2012","unstructured":"Gomes MLS. Coinfec\u00e7\u00e3o leishmaniose visceral e Aids no Brasil, 2001 a 2010. Rio de Janeiro: Disserta\u00e7\u00e3o [Mestrado em Epidemiologia e Sa\u00fade P\u00fablica] - Escola Nacional de Sa\u00fade P\u00fablica Sergio Arouca; 2012."},{"issue":"2","key":"6051_CR30","first-page":"91","volume":"14","author":"AJM Caldas","year":"2013","unstructured":"Caldas AJM, Lisb\u00f4a LLC, Silva PF, Coutinho NPS. SilvaTC. Perfil das crian\u00e7as com leishmaniose visceral que evolu\u00edram para \u00f3bito, falha terap\u00eautica e recidiva em hospital de S\u00e3o Lu\u00eds, Maranh\u00e3o. Rev Pesq Sa\u00fade. 2013;14(2):91\u20135.","journal-title":"Rev Pesq Sa\u00fade"},{"issue":"1","key":"6051_CR31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/infdis\/jix277","volume":"216","author":"S Marquet","year":"2017","unstructured":"Marquet S, Bucheton B, Reymond C, Argiro L, EL-Safi SH, Kheir MM, et al. Exome sequencing identifies two variants of the Alkylglycerol Monooxygenase gene as a cause of relapses in visceral Leishmaniasis in children, in Sudan. J Infect Dis. 2017;216(1):22\u20138. https:\/\/doi.org\/10.1093\/infdis\/jix277.","journal-title":"J Infect Dis"},{"issue":"6","key":"6051_CR32","doi-asserted-by":"publisher","first-page":"e705","DOI":"10.1371\/journal.pntd.0000705","volume":"4","author":"S Gorski","year":"2010","unstructured":"Gorski S, Collin SM, Ritmeijer K, Keus K, Gatluak F, Mueller M, et al. Visceral leishmaniasis relapse in southern Sudan (1999-2007): a retrospective study of risk factors and trends. PLoS Negl Trop Dis. 2010;4(6):e705. https:\/\/doi.org\/10.1371\/journal.pntd.0000705.","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"6051_CR33","doi-asserted-by":"publisher","first-page":"e2536","DOI":"10.1371\/journal.pntd.0002536","volume":"8","author":"S Burza","year":"2014","unstructured":"Burza S, Sinha PK, Mahajan R, Lima MA, Mitra G, Verma N, et al. Risk factors for visceral Leishmaniasis relapse in Immunocompetent patients following treatment with 20 mg\/kg liposomal amphotericin B (Ambisome) in Bihar, India. PLoS Negl Trop Dis. 2014;8(1):e2536. https:\/\/doi.org\/10.1371\/journal.pntd.0002536.","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"6051_CR34","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1365-3156.2010.02694.x","volume":"16","author":"M Kajaia","year":"2011","unstructured":"Kajaia M, Morse DL, Kamkamidze G, Butsashvili M, Chubabria G, Zenaishvili O, et al. Risk factors for relapse of visceral leishmaniasis in Georgia. Tropical Med Int Health. 2011;16(2):186\u201392. https:\/\/doi.org\/10.1111\/j.1365-3156.2010.02694.x.","journal-title":"Tropical Med Int Health"},{"issue":"3","key":"6051_CR35","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1086\/380971","volume":"3","author":"S Sundar","year":"2004","unstructured":"Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis. 2004;3(3):377\u201383. https:\/\/doi.org\/10.1086\/380971.","journal-title":"Clin Infect Dis"},{"key":"6051_CR36","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3389\/fcimb.2018.00394","volume":"8","author":"MD Hermida","year":"2018","unstructured":"Hermida MD, de Melo CVB, Lima IDS, Oliveira GGS, dos Santos WLC. Histological disorganization of spleen compartments and severe visceral Leishmaniasis. Front Cell Infect Microbiol. 2018;8:394. https:\/\/doi.org\/10.3389\/fcimb.2018.00394.","journal-title":"Front Cell Infect Microbiol"},{"issue":"2","key":"6051_CR37","doi-asserted-by":"publisher","first-page":"133","DOI":"10.7326\/0003-4819-127-2-199707150-00007","volume":"127","author":"S Sundar","year":"1997","unstructured":"Sundar S, Agrawal NK, Sinha PR, Horwith GS, Murray HW. Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann Intern Med. 1997;127(2):133\u20137. https:\/\/doi.org\/10.7326\/0003-4819-127-2-199707150-00007.","journal-title":"Ann Intern Med"},{"issue":"3","key":"6051_CR38","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1093\/jac\/dkg356","volume":"52","author":"F Laguna","year":"2003","unstructured":"Laguna F, Vilela S, Jim\u00e9nez-Mej\u00edas ME, Sirera G, Torre-Cisneros J, Ribera E, et al. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. J Antimicrob Chemoter. 2003;52(3):464\u20138. https:\/\/doi.org\/10.1093\/jac\/dkg356.","journal-title":"J Antimicrob Chemoter"},{"issue":"17","key":"6051_CR39","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.2165\/00003495-200464170-00004","volume":"64","author":"DR Goldsmith","year":"2004","unstructured":"Goldsmith DR, Perry CM. Amphotericin B lipid complex in visceral Leishmaniasis. Drugs. 2004;64(17):1905\u201311. https:\/\/doi.org\/10.2165\/00003495-200464170-00004.","journal-title":"Drugs."},{"issue":"12","key":"6051_CR40","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.4049\/jimmunol.152.12.5949","volume":"152","author":"EM Carvalho","year":"1994","unstructured":"Carvalho EM, Bacellar O, Brownell C, Regis T, Coffman RL, Reed SG. Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. J Immunol. 1994;152(12):5949\u201356.","journal-title":"J Immunol"},{"issue":"2","key":"6051_CR41","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/iid3.285","volume":"8","author":"AVA da Silva","year":"2020","unstructured":"da Silva AVA, Souza TL, Figueiredo FB, Mendes-Jr AAV, Ferreira LC, Filgueira CPB, et al. Detection of amastigotes and histopathological alterations in the thymus of Leishmania infantum-infected dogs. Immun Inflamm Dis. 2020;8(2):127\u201339. https:\/\/doi.org\/10.1002\/iid3.285.","journal-title":"Immun Inflamm Dis"},{"issue":"6","key":"6051_CR42","doi-asserted-by":"publisher","first-page":"e1153","DOI":"10.1371\/journal.pntd.0001153","volume":"5","author":"GF Cota","year":"2011","unstructured":"Cota GF, Sousa MR, Rabello A. Predictors of visceral Leishmaniasis relapse in HIV-infected patients: a systematic review. PLoS Negl Trop Dis. 2011;5(6):e1153. https:\/\/doi.org\/10.1371\/journal.pntd.0001153.","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"6051_CR43","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.bjid.2015.07.004","volume":"19","author":"LGF T\u00e1vora","year":"2015","unstructured":"T\u00e1vora LGF, Nogueira MB, Gomes ST. Visceral Leishmaniasis\/HIV co-infection in Northeast Brazil: evaluation of outcome. Braz J Infect Dis. 2015;19(6):651\u20136. https:\/\/doi.org\/10.1016\/j.bjid.2015.07.004.","journal-title":"Braz J Infect Dis"},{"issue":"6","key":"6051_CR44","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1128\/IAI.62.6.2614-2618.1994","volume":"62","author":"AM Da-Cruz","year":"1994","unstructured":"Da-Cruz AM, Concei\u00e7\u00e3o-Silva F, Bertho AL, Coutinho SG. Leishmania-reactive CD4+ and CD8+ T cells associated with cure of human cutaneous leishmaniasis. Infect Immun. 1994;62(6):2614\u20138. https:\/\/doi.org\/10.1128\/IAI.62.6.2614-2618.1994.","journal-title":"Infect Immun"},{"issue":"9","key":"6051_CR45","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.4049\/jimmunol.159.9.4467","volume":"159","author":"CI Brodskyn","year":"1997","unstructured":"Brodskyn CI, Barral A, Boaventura V, Carvalho E, Barral-Netto M. Parasite-driven in vitro human lymphocyte cytotoxicity against autologous infected macrophages from mucosal leishmaniasis. J Immunol. 1997;159(9):4467\u201373.","journal-title":"J Immunol"},{"issue":"7","key":"6051_CR46","doi-asserted-by":"publisher","first-page":"e1003504","DOI":"10.1371\/journal.ppat.1003504","volume":"9","author":"FO Novais","year":"2013","unstructured":"Novais FO, Carvalho LP, Graff JW, Beiting DP, Ruthel G, Roos DS, et al. Cytotoxic T cells mediate pathology and metastasis in cutaneous leishmaniasis. PLoS Pathog. 2013;9(7):e1003504. https:\/\/doi.org\/10.1371\/journal.ppat.1003504.","journal-title":"PLoS Pathog"},{"issue":"2","key":"6051_CR47","doi-asserted-by":"publisher","first-page":"e1006196","DOI":"10.1371\/journal.ppat.1006196","volume":"13","author":"FO Novais","year":"2017","unstructured":"Novais FO, Carvalho AM, Clark ML, Carvalho LP, Beiting DP, Brodsky IE, et al. CD8+ T cell cytotoxicity mediates pathology in the skin by inflammasome activation and IL-1\u03b2 production. PLoS Pathog. 2017;13(2):e1006196. https:\/\/doi.org\/10.1371\/journal.ppat.1006196.","journal-title":"PLoS Pathog"},{"issue":"11","key":"6051_CR48","doi-asserted-by":"publisher","first-page":"5559","DOI":"10.1128\/IAI.67.11.5559-5566.1999","volume":"67","author":"C Mary","year":"1999","unstructured":"Mary C, Auriault V, Faug\u00e9re B, Dessein AJ. Control of Leishmania infantum infection is associated with CD81 and gamma interferon- and Interleukin-5-producing CD41 antigen-specific T cells. Infect Immun. 1999;67(11):5559\u201366. https:\/\/doi.org\/10.1128\/IAI.67.11.5559-5566.1999.","journal-title":"Infect Immun"},{"issue":"11\u201312","key":"6051_CR49","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/j.0141-9838.2004.00672.x","volume":"25","author":"P Tsagozis","year":"2003","unstructured":"Tsagozis P, Karagouni E, Dotsika E. CD8(+) T cells with parasite-specific cytotoxic activity and a Tc1 profile of cytokine and chemokine secretion develop in experimental visceral leishmaniasis. Parasite Immunol. 2003;25(11\u201312):569\u201379. https:\/\/doi.org\/10.1111\/j.0141-9838.2004.00672.x.","journal-title":"Parasite Immunol"},{"issue":"2","key":"6051_CR50","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.parint.2005.02.005","volume":"54","author":"P Tsagozis","year":"2005","unstructured":"Tsagozis P, Karagouni E, Dotsika E. Function of CD8+ T lymphocytes in a selfcuring mouse model of visceral leishmaniasis. Parasitol Int. 2005;54(2):139\u201346. https:\/\/doi.org\/10.1016\/j.parint.2005.02.005.","journal-title":"Parasitol Int"},{"issue":"1","key":"6051_CR51","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1186\/s12879-014-0653-6","volume":"14","author":"H Kaushal","year":"2014","unstructured":"Kaushal H, Bras-Gon\u00e7alves R, Negi NS, Lemesre JL, Papierok G, Salotra P. Role of CD8+ T cells in protection against Leishmania donovani infection in healed visceral Leishmaniasis individuals. BMC Infect Dis. 2014;14(1):653. https:\/\/doi.org\/10.1186\/s12879-014-0653-6.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"6051_CR52","first-page":"337","volume":"10","author":"TGSL Lopes","year":"2011","unstructured":"Lopes TGSL, Schinoni MI. Aspectos gerais da hepatite B. R Ci Med Biol. 2011;10(3):337\u201344.","journal-title":"R Ci Med Biol"},{"issue":"Suppl 1","key":"6051_CR53","doi-asserted-by":"publisher","first-page":"S115","DOI":"10.2223\/JPED.378","volume":"75","author":"LH Carvalho","year":"1999","unstructured":"Carvalho LH. Mononucleose infecciosa [infectious mononucleosis]. J Pediatr. 1999;75(Suppl 1):S115\u201325.","journal-title":"J Pediatr"},{"issue":"7109","key":"6051_CR54","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nature05115","volume":"443","author":"CL Day","year":"2006","unstructured":"Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006;443(7109):350\u20134. https:\/\/doi.org\/10.1038\/nature05115.","journal-title":"Nature."},{"issue":"11","key":"6051_CR55","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1038\/ni1515","volume":"8","author":"DE Kaufmann","year":"2007","unstructured":"Kaufmann DE, Kavanagh DG, Pereyra F, Zaunders JJ, Mackey EW, Miura T, et al. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol. 2007;8(11):1246\u201354. https:\/\/doi.org\/10.1038\/ni1515.","journal-title":"Nat Immunol"},{"issue":"2","key":"6051_CR56","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/infdis\/jit401","volume":"209","author":"S Gautam","year":"2014","unstructured":"Gautam S, Kumar R, Singh N, Singh AK, Rai M, Sacks D, et al. CD8 T cell exhaustion in human visceral leishmaniasis. J Infect Dis. 2014;209(2):290\u20139. https:\/\/doi.org\/10.1093\/infdis\/jit401.","journal-title":"J Infect Dis"},{"key":"6051_CR57","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3389\/fcimb.2018.00427","volume":"8","author":"T Marlais","year":"2018","unstructured":"Marlais T, Bhattacharyya T, Singh OP, Mertens P, Gilleman Q, Thunissen C, et al. Visceral Leishmaniasis IgG1 Rapid Monitoring of Cure vs. Relapse, and Potential for Diagnosis of Post Kala-Azar Dermal Leishmaniasis. Front Cell Infect Microbiol. 2018;8:427. https:\/\/doi.org\/10.3389\/fcimb.2018.00427.","journal-title":"Front Cell Infect Microbiol"},{"issue":"10","key":"6051_CR58","doi-asserted-by":"publisher","first-page":"e3273","DOI":"10.1371\/journal.pntd.0003273","volume":"8","author":"T Bhattacharyya","year":"2014","unstructured":"Bhattacharyya T, Ayandeh A, Falconar AK, Sundar S, El-Safi S, Gripenberg MA, et al. IgG1 as a potential biomarker of post-chemotherapeutic relapse in visceral Leishmaniasis and adaptation to a rapid diagnostic test. PLoS Negl Trop Dis. 2014;8(10):e3273. https:\/\/doi.org\/10.1371\/journal.pntd.0003273.","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"6051_CR59","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/cid\/ciy1062","volume":"69","author":"G Mollett","year":"2019","unstructured":"Mollett G, Hinckel BCB, Bhattacharyya T, Marlais T, Singh OP, Mertens P, et al. Detection of immunoglobulin G1 against rK39 improves monitoring of treatment outcomes in visceral Leishmaniasis. Clin Infect Dis. 2019;69(7):1130\u20135. https:\/\/doi.org\/10.1093\/cid\/ciy1062.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"6051_CR60","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1128\/iai.72.2.863-870.2004","volume":"72","author":"R Ravindran","year":"2004","unstructured":"Ravindran R, Anam K, Bairagi BC, Saha B, Pramanik N, Guha SK, et al. Characterization of immunoglobulin G and its subclass response to Indian Kala-Azar infection before and after chemotherapy. Infect Immun. 2004;72(2):863\u201370. https:\/\/doi.org\/10.1128\/iai.72.2.863-870.2004.","journal-title":"Infect Immun"},{"issue":"12","key":"6051_CR61","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1086\/588387","volume":"197","author":"S Ganguly","year":"2008","unstructured":"Ganguly S, Das NK, Panja M, Pal S, Modak D, Rahaman M, et al. Increased levels of interleukin-10 and IgG3 are hallmarks of Indian post-kala-azar dermal leishmaniasis. J Infect Dis. 2008;197(12):1762\u201371. https:\/\/doi.org\/10.1086\/588387.","journal-title":"J Infect Dis"},{"issue":"1\u20132","key":"6051_CR62","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jim.2010.06.011","volume":"360","author":"IT Gomes","year":"2010","unstructured":"Gomes IT, Carvalho SFG, Rocha RDR, Peruhype-Magalhaes V, Dietze R, Martins-Filho OA, et al. Anti-Leishmania chagasi immunoglobulin G3 detected by flow cytometry for early cure assessment in American visceral leishmaniasis. J Immunol Methods. 2010;360(1\u20132):76\u201383. https:\/\/doi.org\/10.1016\/j.jim.2010.06.011.","journal-title":"J Immunol Methods"},{"key":"6051_CR63","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/978-94-024-0921-5_4","volume":"941","author":"T Tanaka","year":"2016","unstructured":"Tanaka T, Narazaki M, Masuda K, Kishimoto T. Regulation of IL-6 in immunity and diseases. Adv Exp Med Biol. 2016;941:79\u201388. https:\/\/doi.org\/10.1007\/978-94-024-0921-5_4.","journal-title":"Adv Exp Med Biol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06051-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06051-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06051-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T06:36:40Z","timestamp":1698907000000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06051-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6051"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06051-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-127021\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,20]]},"assertion":[{"value":"11 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been reviewed and approved by the Ethics Committee of Hospital Eduardo de Menezes (number 68118117.3.3002.5124), Instituto Rene Rachou (number 68118117.3.3001.5091) and Instituto Oswaldo Cruz - Funda\u00e7\u00e3o Oswaldo Cruz (number 68118117.3.1001.5248). The patients\/participants provided their written informed consent to participate in this study. We also confirm that all methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"369"}}